Interview: Francisco Kuri Breña, Director of New Developments & Irma Aguilar Delfín, Head of Genomics Research, Landsteiner – Mexico
13.05.2015
Related Interviews
Luis Calderon – General Manager, Biogen Mexico
Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and the impact of the country’s ongoing health reforms. In my experience,…
Omar Lugo Aguirre – Country Lead, nPVU & Market Access, Operations…
UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region…
Constanza Losada – President & CEO, Pfizer Mexico
Recently appointed CEO and president for Pfizer Mexico, Constanza Losada, outlines the exciting challenge of taking on leadership for such an important affiliate during the COVID-19 pandemic and how Pfizer…
APAC / Six Trends for Emerging Biotech/Biopharma to Watch in 2022
To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC…
Pharma Faces / Genmab CEO On 50:50 Partnerships & Creating “Iconic” Innovation Powerhouse
Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed…
Spain / 5 Key Industry Trends 2021
According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends…
Latest Report
